Page last updated: 2024-08-25

oxazolidin-2-one and Disease Exacerbation

oxazolidin-2-one has been researched along with Disease Exacerbation in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Havekes, LM; Jukema, JW; Kühnast, S; Landmesser, U; Lüscher, TF; Pieterman, E; Princen, HM; Rensen, PC; Simic, B; van der Hoorn, JW; van der Tuin, SJ; van Klinken, JB; Willems van Dijk, K	1
Dembo, T; Kato, Y; Takeda, H; Tanahashi, N	1

Reviews

1 review(s) available for oxazolidin-2-one and Disease Exacerbation

Article	Year
Delayed recurrent ischemic stroke after initial good recovery from pneumococcal meningitis. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:6 Topics: Acetamides; Brain Damage, Chronic; Brain Ischemia; Ceftriaxone; Community-Acquired Infections; Constriction, Pathologic; Dexamethasone; Disease Progression; Drug Therapy, Combination; Humans; Linezolid; Male; Meningitis, Pneumococcal; Meropenem; Middle Aged; Oxazolidinones; Platelet Aggregation Inhibitors; Prednisolone; Recurrence; Thienamycins	2012

Article

Year

Delayed recurrent ischemic stroke after initial good recovery from pneumococcal meningitis.

Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:6

Topics: Acetamides; Brain Damage, Chronic; Brain Ischemia; Ceftriaxone; Community-Acquired Infections; Constriction, Pathologic; Dexamethasone; Disease Progression; Drug Therapy, Combination; Humans; Linezolid; Male; Meningitis, Pneumococcal; Meropenem; Middle Aged; Oxazolidinones; Platelet Aggregation Inhibitors; Prednisolone; Recurrence; Thienamycins

2012

Other Studies

1 other study(ies) available for oxazolidin-2-one and Disease Exacerbation

Article	Year
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. European heart journal, 2015, Jan-01, Volume: 36, Issue:1 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein	2015

Article

Year

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.

European heart journal, 2015, Jan-01, Volume: 36, Issue:1

Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein

2015